1. Home
  2. EUDA vs LUNG Comparison

EUDA vs LUNG Comparison

Compare EUDA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EUDA Health Holdings Limited

EUDA

EUDA Health Holdings Limited

HOLD

Current Price

$12.37

Market Cap

68.7M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.27

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EUDA
LUNG
Founded
2021
1995
Country
Singapore
United States
Employees
N/A
N/A
Industry
Blank Checks
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
72.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
EUDA
LUNG
Price
$12.37
$1.27
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$55.00
$5.38
AVG Volume (30 Days)
160.2K
727.7K
Earning Date
12-19-2023
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
$134.73
$2.48
Revenue Next Year
$195.03
$18.46
P/E Ratio
$123.62
N/A
Revenue Growth
N/A
8.01
52 Week Low
$0.33
$1.28
52 Week High
$11.47
$7.05

Technical Indicators

Market Signals
Indicator
EUDA
LUNG
Relative Strength Index (RSI) 95.59 33.99
Support Level $1.66 N/A
Resistance Level N/A $1.93
Average True Range (ATR) 0.77 0.11
MACD 1.31 -0.04
Stochastic Oscillator 74.74 0.79

Price Performance

Historical Comparison
EUDA
LUNG

About EUDA EUDA Health Holdings Limited

EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: